Developed skills and lines of research
Domenico Mattoscio earned his master’s degree in Biological Sciences from the University of Molise in 2006. That same year, as a research fellow, he began collaborating with FFC Ricerca to study the role of platelets in cystic fibrosis and later to identify innovative treatments targeting inflammation and chronic pulmonary infection.
In 2011, he obtained a PhD from the University of Chieti and worked as a post-doctoral researcher at the European Institute of Oncology (IEO) in Milan from 2011 to 2016. He then returned to the University of Chieti, where he has been a researcher in Applied Medical Technical Sciences at the Department of Medical, Oral, and Biotechnological Sciences since 2022.
His current studies focus on modulating the activity of immune-inflammatory cells to provide therapeutic benefits for conditions such as cystic fibrosis and cancer, both characterized by significant chronic inflammation.
Since 2022, he has led a project aimed at determining new therapeutic approaches to reduce the pulmonary inflammatory response caused by platelet hyperactivation.
Projects funded by FFC Ricerca as Principal Investigator or as Research Manager
FFC#12/2024
Targeting immune system to restrain cystic fibrosis airway inflammation
FFC#11/2022
Targeting platelet activation with pro-resolving mediators: an innovative strategy to dampen lung inflammation in cystic fibrosis
Publications from FFC Research projects
Resolvin D1 and D2 reduce SARS-CoV-2-induced inflammatory responses in cystic fibrosis macrophages. Recchiuti A, Patruno S, Mattoscio D, Isopi E, Pomilio A, Lamolinara A, Iezzi M, Pecce R, Romano M. FASEB J. 2021 Apr;35(4):e21441.
• Roles of Specialized Pro-Resolving Lipid Mediators in Autophagy and Inflammation. Recchiuti A, Isopi E, Romano M, Mattoscio D. Int J Mol Sci. 2020 Sep 10;21(18):6637.
• Resolvin D1 Reduces Lung Infection and Inflammation Activating Resolution in Cystic Fibrosis. Isopi E, Mattoscio D, Codagnone M, Mari VC, Lamolinara A, Patruno S, D’Aurora M, Cianci E, Nespoli A, Franchi S, Gatta V, Dubourdeau M, Moretti P, Di Sabatino M, Iezzi M, Romano M, Recchiuti A. Front Immunol. 2020 Apr 28;11:581.
• Roles, Actions, and Therapeutic Potential of Specialized Pro-resolving Lipid Mediators for the Treatment of Inflammation in Cystic Fibrosis. Recchiuti A, Mattoscio D, Isopi E. Front Pharmacol. 2019 Apr 2;10:252.
• Resolvin D1 enhances the resolution of lung inflammation caused by long-term Pseudomonas aeruginosa infection. Codagnone M, Cianci E, Lamolinara A, Mari VC, Nespoli A, Isopi E, Mattoscio D, Arita M, Bragonzi A, Iezzi M, Romano M, Recchiuti A. Mucosal Immunol. 2018 Jan;11(1):35-49
• Transcriptional regulation of the human FPR2/ALX gene: evidence of a heritable genetic variant that impairs promoter activity. Simiele F, Recchiuti A, Mattoscio D, De Luca A, Cianci E, Franchi S, Gatta V, Parolari A, Werba JP, Camera M, Favaloro B, Romano M. FASEB J. 2012 Mar;26(3):1323-33.
• Proteomics investigation of human platelets in healthy donors and cystic fibrosis patients by shotgun nUPLC-MSE and 2DE: a comparative study. Pieroni L, Finamore F, Ronci M, Mattoscio D, Marzano V, Mortera SL, Quattrucci S, Federici G, Romano M, Urbani A. Mol Biosyst. 2011 Mar;7(3):630-9.
• Cystic fibrosis transmembrane conductance regulator (CFTR) expression in human platelets: impact on mediators and mechanisms of the inflammatory response. Mattoscio D, Evangelista V, De Cristofaro R, Recchiuti A, Pandolfi A, Di Silvestre S, Manarini S, Martelli N, Rocca B, Petrucci G, Angelini DF, Battistini L, Robuffo I, Pensabene T, Pieroni L, Furnari ML, Pardo F, Quattrucci S, Lancellotti S, Davì G, Romano M. FASEB J. 2010 Oct;24(10):3970-80